A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144 or LN-145) in Patients With Solid Tumors

What is the purpose of this trial?

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with pembrolizumab. TIL as a single-therapy will be evaluated with LN-145 only.



Iovance Biotherapeutics

Start Date: 12/19/2018

End Date: 04/30/2020

Last Updated: 01/27/2019

Study HIC#: 2000023142

Get Involved

For more information about this study, contact:
Kira Pavlik
+1 203-785-6540
kira.pavlik@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image